<DOC>
	<DOCNO>NCT00400101</DOCNO>
	<brief_summary>Influenza virosomes represent innovative human-compatible antigen delivery system already proven suitability subunit vaccine design . The aim study proof concept virosomes also use elicit high titer antibody synthetic peptide derive circumsporozoite protein apical-membrane-antigen 1 formulation safe human .</brief_summary>
	<brief_title>Phase Ia Malaria Vaccine Trial Two Virosome-Formulated Peptides</brief_title>
	<detailed_description>Influenza virosomes represent innovative human-compatible antigen delivery system already proven suitability subunit vaccine design . The aim study proof concept virosomes also use elicit high titer antibody synthetic peptide . The specific objective demonstrate safety immunogenicity two virosome-formulated P. falciparum protein derive synthetic peptide antigen give two different dos alone combination . Methodology The design single blind , randomize , placebo control , dose-escalating study involve 46 healthy Caucasian volunteer age 18-45 year . Five group 8 subject receive virosomal formulation contain 10 ug 50 ug AMA 49-CPE , apical membrane antigen-1 ( AMA-1 ) derive synthetic phospatidylethanolamine ( PE ) -peptide conjugate 10 ug 50 ug UK39 , circumsporozoite protein ( CSP ) derive synthetic PE-peptide conjugate 50 ug antigen . A control group 6 subject receive unmodified virosomes . Virosomal formulation antigen ( designate PEV301 PEV302 AMA-1 CSP virosomal vaccine , respectively ) unmodified virosomes injected i. m. day 0 , 60 180 .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy volunteer sex , age 18 45 year , BMI &gt; 18.5 &lt; 30 include give write informed consent Chronix acute illness , immunosuppression , live past malaria endemic area , visit area last 12 month , history clinical malaria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Plasmodium</keyword>
	<keyword>falciparum</keyword>
	<keyword>Phase I</keyword>
	<keyword>Peptide</keyword>
	<keyword>Virosome</keyword>
	<keyword>safety</keyword>
	<keyword>immunogenicity</keyword>
</DOC>